Turnstone Biologics Appoints William Waddill to its Board of Directors
16 avr. 2024 09h00 HE
|
Turnstone Biologics Corp.
Turnstone Biologics appoints biotechnology industry veteran, William Waddill, to its Board of Directors.
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights
21 mars 2024 17h06 HE
|
Turnstone Biologics Corp.
Turnstone reports fourth quarter and full year 2023 financial results and provides recent business highlights.
Turnstone Biologics to Participate in Upcoming Investor Conferences
21 févr. 2024 06h00 HE
|
Turnstone Biologics Corp.
Turnstone to present and participate in TD Cowen 44th Annual Global Health Care Conference and Leerink Partners Global Biopharma Conference 2024.
Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.
20 févr. 2024 17h00 HE
|
Turnstone Biologics Corp.
Turnstone announced with sadness that the Company's Chief Legal Officer passed away following prolonged battle with cancer.
Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference
27 nov. 2023 06h00 HE
|
Turnstone Biologics Corp.
Dr. Sammy Farah, President and CEO of Turnstone, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York.
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
09 nov. 2023 21h49 HE
|
Turnstone Biologics Corp.
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
03 nov. 2023 06h00 HE
|
Turnstone Biologics Corp.
Posters showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for solid tumors.
Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber
30 oct. 2023 06h00 HE
|
Turnstone Biologics Corp.
Internationally recognized cancer immunotherapy thought leader, Dr. Weber, will help guide Turnstone’s continued advancement of its Selected TIL therapies
Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
28 sept. 2023 06h00 HE
|
Turnstone Biologics Corp.
Turnstone Biologics to present preclinical data for its Selected TILs at SITC's 38th Annual Meeting.
Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update
01 sept. 2023 17h57 HE
|
Turnstone Biologics Corp.
Successfully closed upsized IPO, raising $88 million in gross proceeds to continue advancing pipeline of Selected TIL Therapy programsCash position expected to fund operations into second quarter of...